Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 6/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 10/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 2/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30443812 | 0.91 | ERAP2 (0.55) | KISS1RIL23RMAGI3GHSRNPY2R | |
| SCHEMBL31064875 | 0.90 | KISS1R (0.55) | KISS1RIL23RERBB2MAGI3 | |
| SCHEMBL31546312 | 0.88 | KISS1R (0.56) | KISS1RIL23RERBB2MAGI3GHSR | |
| SCHEMBL29636525 | 0.88 | KISS1R (0.53) | KISS1RIL23RGHSRNPY2R | |
| SCHEMBL29476642 | 0.88 | KISS1R (0.53) | KISS1RIL23RGHSR | |
| SCHEMBL13166798 | 0.88 | KISS1R (0.64) | KISS1RIL23R | |
| SCHEMBL30947673 | 0.87 | ERAP2 (0.57) | KISS1RNPY2R | |
| SCHEMBL30946946 | 0.87 | MAGI3 (0.51) | KISS1RMAGI3GHSRNPY2R | |
| SCHEMBL30641908 | 0.87 | NPY1R (0.50) | KISS1RMAGI3GHSRNPY2R | |
| SCHEMBL30641907 | 0.87 | NPY1R (0.50) | KISS1RMAGI3GHSRNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | PEPTISTAR INC. (JP) | 2024-09-26 | — | — | US | disclosed |
| EP-4365184-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | Peptistar Inc. (JP) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023277186-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | ペプチスター株式会社 | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | HDGF, VIP, NPPA | KISS1R 3107/4885IL23R 2141/4885ERBB2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.